Teva Branded Pharmaceutical Products R&D

103 total trials 64 currently recruiting 37 completed

Trial Pipeline

RECRUITING Phase 2

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866

RECRUITING Phase 2

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

NCT06807463

RECRUITING Phase 3

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619

RECRUITING Phase 2

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237

RECRUITING Phase 1

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT06480552

RECRUITING Phase 3

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267

ACTIVE NOT RECRUITING Phase 1

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

NCT06625177

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013

COMPLETED Phase 1

A Study to Assess New Formulations of TEV-56286

NCT06911567

COMPLETED Phase 1

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

NCT06290102

COMPLETED Phase 1

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170

COMPLETED Phase 3

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

NCT05693935

COMPLETED Phase 2

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05499130

COMPLETED Phase 4

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959

COMPLETED Phase 1

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

NCT04682353

COMPLETED Phase 3

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110

COMPLETED Phase 3

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

NCT04458857

COMPLETED Phase 3

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

NCT03813238

COMPLETED Phase 3

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

NCT03571256

COMPLETED Phase 3

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133

COMPLETED Phase 1

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

NCT02817464

COMPLETED Phase 3

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

NCT02452190

COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)

NCT02365636

COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee

NCT02068599

COMPLETED Phase 2

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

NCT02025556

COMPLETED Phase 3

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640

COMPLETED Phase 3

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766

COMPLETED Phase 1

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

NCT01879748

COMPLETED Phase 3

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

NCT01857323

COMPLETED Phase 3

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

NCT01789970

COMPLETED Phase 2

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368

COMPLETED Phase 4

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

NCT01723228

COMPLETED Phase 3

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

NCT01287039

COMPLETED Phase 3

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

NCT01307319

COMPLETED Phase 2

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

NCT01085097

COMPLETED Phase 2

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

NCT01058863

COMPLETED

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

NCT00936676

COMPLETED Phase 3

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006

COMPLETED Phase 2

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

NCT00724048

COMPLETED Phase 2

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00696332

COMPLETED Phase 3

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00509145

COMPLETED Phase 4

Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma

NCT00530062

COMPLETED Phase 2

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273

COMPLETED Phase 2

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

NCT00054964

COMPLETED Phase 3

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

NCT00203164

Phase Distribution

PhaseTrial count
Phase 1 35
Phase 2 46
Phase 3 18
Phase 4 3

What the Pipeline for Teva Branded Pharmaceutical Products R&D Shows

According to the ClinicalTrials.gov registry, Teva Branded Pharmaceutical Products R&D is linked to 103 US clinical trials across every stage of research activity. Of those, 64 studies are currently recruiting — about 62% of the sponsor's indexed portfolio — and 37 are already marked complete, representing roughly 36% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Teva Branded Pharmaceutical Products R&D reports 21 late-stage studies (Phase 3 and Phase 4 combined) and 81 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Teva Branded Pharmaceutical Products R&D is Asthma with 13 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial